EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus

Douglas J. Fort, Enos L. Stover, James R. Rayburn, Mendi Hull, John A. Bantle

Teratogenesis, Carcinogenesis, and Mutagenesis · 1993-01 · 13 (1) · 35-45

DOI: 10.1002/tcm.1770130105 ↗
AbstractBibliografische Angaben

Abstract

Abstract Potential mechanisms of trichloroethylene‐induced developmental toxicity were evaluated using FETAX (Frog Embryo Teratogenesis Assay— Xenopus ). Early Xenopus laevis embryos were exposed to trichloroethylene for 96 h in two separate definitive concentration‐response assays with and without an exogenous metabolic activation system (MAS) and inhibited MAS. The MAS was treated with either carbon monoxide or cyclohexene oxide to modulate mixed‐function oxidase (MFO) or epoxide hydrolase activity, respectively. Trichloroethylene metabolites: dichloroacetic acid, trichloroacetic acid, trichloroethanol, and oxalic acid were also evaluated in two separate definitive, static renewal tests. Addition of the MAS decreased the 96 h LC50 and EC50 (malformation) of trichloroethylene 1.8‐fold and 3.8‐fold, respectively. Addition of the carbon monoxide inhibited MAS decreased the developmental toxicity of activated trichloroethylene to levels approximating that of the parent compound. Cyclohexene oxide‐inhibited MAS substantially increased the developmental toxicity of trichloroethylene. In addition, each of the metabolites tested were significantly less developmental toxic than the parent compound, trichloroethylene. Results indicate that a highly embryotoxic epoxide intermediate, trichloroethylene oxide, formed as the results of MFO mediated metabolism may play a significant role in the developmental toxicity of trichloroethylene in vitro. ©1993 Wiley‐Liss, Inc.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →